XML 31 R7.htm IDEA: XBRL DOCUMENT v3.25.1
STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:    
Net loss $ (14,880,787) $ (7,987,836)
Adjustment to reconcile net loss to net cash used in operating activities:    
Depreciation 27,361 27,361
Stock-based compensation, including the issuance of restricted stock 2,663,539 872,248
Acquired in-process research and development 25,000 543,186
Changes in operating assets and liabilities:    
Collaboration receivable 7,500,000 (7,500,000)
Prepaids and other current assets (4,899,109) 181,707
Accounts payable 477,450 298,816
Accrued expenses (1,498,215) 877,913
Deferred collaboration revenue 295,939 1,497,794
Net cash used in operating activities (10,288,822) (11,188,811)
Cash flows from investing activities:    
Purchase of in-process research and development assets (25,000) (543,186)
Net cash used in investing activities (25,000) (543,186)
Cash flows from financing activities:    
Proceeds from sale of common stock from 2023 Private Placement, net of offering costs   24,084,805
Proceeds from issuance of common stock upon IPO, net of offering costs   14,250,311
Payment of financing costs related to the 2023 Private Placement (131,918)  
Proceeds from subscription receivable 11,250  
Proceeds from the exercise of stock options 1,975 89,947
Proceeds from the exercise of warrants 2,141,128  
Proceeds from sale of common stock, net of offering costs 14,004,381  
Net cash provided by financing activities 16,026,816 38,425,063
Net increase in cash and cash equivalents 5,712,994 26,693,066
Cash and cash equivalents as of beginning of the year 32,626,768 5,933,702
Cash and cash equivalents as of end of the year $ 38,339,762 32,626,768
Supplemental disclosures of non-cash financing activities:    
Conversion of convertible preferred stock upon IPO   8,793,637
Conversion of convertible promissory notes upon IPO   12,965,480
Subscription receivable related to warrant exercise   11,250
Financing costs related to the 2023 Private Placement in accrued expenses and accounts payable   $ 131,918